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Background: An innovative approach to lung volume reduction (LVR) for emphysema is introduced in the design
of the Sequential Segmental Treatment of Emphysema with Upper Lobe Predominance (STEP-UP) trial where
vapour ablation is administered bilaterally over the course of two sessions and is used to target only the most
diseased upper lobe segments. By dividing the procedure into two sessions, there is potential to increase the total
volume treated per patient but reduce volume treated and energy delivered per session. This is expected to
correlate with improvements in vapour ablation’s safety and efficacy profiles.
Methods: The STEP-UP trial is a randomized, controlled, open-label, 12 month study of patients with upper lobe
predominant emphysema (ULPE). The trial compares patients receiving standard medical management alone
against patients receiving bilateral vapour ablation in addition to standard medical management. An intended
sixty nine subjects will be randomized at a 2:1 (treatment arm:control arm) ratio. Inclusion criteria include a forced
expiratory volume in 1 second (FEV1) between 20% and 45% predicted, total lung capacity > 100% predicted, residual
volume > 150% predicted, marked dyspnea scoring≥ 2 on the modified Medical Research Council (mMRC) scale, and
PaCO2≤ 50 mm Hg. The primary endpoints are the change in FEV1 %predicted and St. George Respiratory Questionnaire
(SGRQ) score between the treatment and control arm at 12 months. Adverse events will be monitored as secondary
endpoints along with other efficacy outcomes at 6 and 12 months.
Discussion: Vapour ablation can reduce lung volume in the presence of collateral ventilation (CV). Due to this ability, it can
be used to target specifically the more diseased segments of each upper lobe. Safety and efficacy outcomes are expected
to improve by considering which segments to treat along with the volume treated per session and per patient.
Trial registration: ClinicalTrials.gov NCT01719263.
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In 2004, the World Health Organization estimated that
64 million people have chronic obstructive pulmonary dis-
ease (COPD) [1]. Emphysema, a subset of COPD, dam-
ages the alveoli causing hyperinflation and reduced gas
exchange resulting in a decrease in pulmonary function,
shortness of breath and a decline in the patient’s quality
of life. Although there is presently no cure for this* Correspondence: arschang.valipour@wienkav.at
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unless otherwise stated.progressive disease, data from the randomized National
Emphysema Treatment Trial (NETT) identifies lung
volume reduction surgery (LVRS) as an effective treat-
ment for patients with emphysema [2]. Patients with
upper lobe predominant emphysema (ULPE) and low ex-
ercise capacity had the best results with LVRS. By redu-
cing the more diseased upper lobe, hyperinflation is
reduced as measured by residual volume reduction and
the better functioning lower lobes are preserved.
Although results from the NETT demonstrated an im-
provement in pulmonary function such as FEV1, exercise
capability, and quality of life post-surgery, the NETT alsol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ated with surgery. Complications included prolonged
hospital stays (25% >30 days), air leak (~90%), and re-
spiratory or cardiac complications [2-4]. These compli-
cations have limited the adoption of LVRS as a routine
therapy for patients with severe emphysema and have
presented a medical need for an alternate effective
method to achieve lung volume reduction (LVR) with an
improved safety profile. To avoid the associated risk of sur-
gery, various bronchoscopic techniques to induce LVR have
emerged [5-8]. One bronchoscopic technique is vapour ab-
lation (InterVapor, Uptake Medical, California, USA).
Vapour ablation is a minimally invasive technique in
which emphysematous lung regions are thermally ablated
by bronchoscopic delivery of water vapour to targeted re-
gions of lung [6,9]. Vapour ablation is a bronchoscopic
therapy that selectively targets emphysematous lung tissue
resulting in a reduction of air and tissue volumes. The lar-
gest study to date for vapour ablation is the VAPOR trial.
The VAPOR trial was designed for unilateral treatment of
an entire lobe in 44 patients with ULPE and resulted in
significant improvements in lung function, exercise cap-
ability, and health-related quality of life with acceptable
morbidity [9,10]. The trial proved vapour ablation success-
fully reduces lung volume (Figure 1) and results demon-
strated that at 6 months post therapy, 83% of the subjects
had clinically relevant improvement in either forced ex-
piratory volume in 1 second (FEV1) or St. George Respira-
tory Questionnaire (SGRQ) quality of life assessment. 55%
of subjects had improvements in FEV1 of ≥ 12% and 73%
of subjects had improvements in the SGRQ total score
of ≥ 4 units at 6 months [9,10].
Post hoc analyses of the VAPOR trial cohort indicated
that the occurrence of serious adverse events (SAEs) typic-
ally increases with the volume treated per session (Figure 2)
[11]. Analysis also revealed an inflection point at 1700 ml
treated above which the SAE rate was 54% and below
which the SAE rate was 10% [11]. An innovative approach
to further limit the volume treated per session is to treat
certain segments individually rather than the entire lobe.
To account for reducing less volume per session, theFigure 1 Radiographic image of lungs pre- and post-vapor ablation t
lobe resulting in targeted lung volume reduction with expansion of lowertreatment can be administered bilaterally over the course
of multiple sessions. It is hypothesized that treating smaller
amounts of lung over the course of multiple sessions will
lead to an improvement in the safety profile while main-
taining or potentially improving efficacy. However, to ef-
fectively induce LVR at the segmental level (rather than at
the lobar level), the treatment must be able to reduce vol-
ume irrespective of the presence of intralobar collateral
ventilation (CV), a common feature of both normal and
emphysematous lungs in humans [12,13]. Vapour ablation
has previously been shown to successfully induce LVR in
the presence of CV and can therefore be used to target em-
physematous tissue at the segmental level in addition to at
the lobar level [14].
The purpose of this paper is to describe the design
and rationale of the Sequential Segmental Treatment of
Emphysema with Upper Lobe Predominance (STEP-UP)
trial. This randomized, controlled trial uses vapour abla-
tion in a stepped bilateral treatment to target individual
segments based on disease state. The STEP-UP trial will
investigate the approach of treating smaller amounts of
lung over the course of two sessions to improve the
safety profile while maintaining or potentially improving
efficacy. Briefly, the STEP-UP trial’s algorithm targets
one segment of an upper lobe during session 1 and steps
up to treating up to two segments of the contralateral
lobe during session 2. The details of the STEP-UP trial’s
algorithm to identify the most diseased segments are
further described in the Methods section. This sequen-
tial segmental approach reduces the overall energy deliv-
ered and the volume of lung treated in a single session
while increasing the volume of lung treated during the en-
tire procedure in comparison to VAPOR. Consequently,
the reduced application of energy per session is expected
to reduce the occurrence of SAEs associated with vapour
ablation and improve the safety profile while the overall
increase in volume of lung treated per procedure is ex-
pected to improve the efficacy profile. Furthermore, stud-
ies have indicated that bilateral treatments, which typically
treat more volume than unilateral treatments, may result
in greater efficacy for pulmonary function measures, suchreatment. Radiographic image shows treatment of the right upper
lobe following vapour ablation (VAPOR trial) [9].
Figure 2 Relationship between adverse event outcomes and volume treated. Graphical representation of volume treated during the VAPOR
trial to demonstrate the risk of having a SAE increases as the volume treated per session increases. Each patient is represented by a bar along the
horizontal axis. Volume treated during the VAPOR trial is on the vertical axis. To promote safety, volume treated per session is now capped at
1700 ml. The SAE rate is 54% for treatments above 1700 ml and is much smaller at 10% for treatments larger than 1700 ml.
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will treat bilaterally in a stepped manner and typically tar-
get a larger volume of emphysematous lung per patient
over the course of two sessions in comparison to the
VAPOR trial. Because not all upper lobe segments are be-
ing treated, it is possible to target and reduce the most
diseased segments of each upper lobe allowing the un-
treated portions of less diseased tissue to expand. This
concept has been proven to yield the best clinical benefit
for the patient and the STEP-UP trial aims to prove that
the concept also holds true on a segmental basis [17-19].
These goals are outlined in Table 1.
Methods/Design
Trial design
The STEP-UP trial is a randomized, controlled, open-label,
12 month study of patients with upper lobe predominantTable 1 Goals for sequential segmental treatment
Step- up goals Reasoning
Treat less lung volume per session as compared to the
lobar treatment sessions in VAPOR
The rate of SAEs in
session is expected
Treat a larger amount of lung volume per patient as
compared to patients in VAPOR
Change in FEV1 is r
Increasing the volu
in an improvement
Treat the most diseased segments in the upper lobes The NETT demonst
lobes to expand yie
diseased portions (
the upper lobes, in
Preserve least diseased segments of the upper lobes Emphysematous tis
lung or lobe. Preser
to improve gas excemphysema. 69 subjects are intended to be randomized at
a 2:1 (treatment arm: control arm) ratio using a blinded
blocked randomization scheme separated by site. The trial
will compare patients receiving standard medical manage-
ment alone against patients receiving bilateral vapour abla-
tion treatment in addition to standard medical management.
Medical management will be consistent with Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) guide-
lines and will consist of a progressive dosage of one or more
bronchodilators, inhaled corticosteroids, and oxygen therapy.
Up to 17 hospital sites will participate in the study.
Screening assessments and HRCT
A completed patient informed consent form is required
from all patients participating in the study. The form is
reviewed and approved by the Institutional Review Board
or Ethics Committee of all participating hospital sites. Thecreases as volume of lung treated increases [11]. Reducing volume per
to reduce the rate of SAEs.
elated to the amount of diseased lung tissue treated per patient.
me of diseased lung to be treated per patient is expected to result
of pulmonary function and efficacy [16-18].
rates that reducing the more diseased upper lobes allow healthier lower
lding the best benefit. It is therefore hypothesized that targeting more
segments) of the upper lobe should allow the least diseased regions of
addition to the lower lobes, to expand [17,19].
sue is typically not homogeneous (equivalently diseased) throughout the
ving the least diseased segments allowing them to expand is expected
hange in the upper lobes.
Table 3 The STEP-UP trial exclusion criteria
1. Any condition that would interfere with the completion of the
study follow-up assessments, bronchoscopy, or that would
adversely affect study outcome.
2. FEV1 < 20% predicted
3. DLCO < 20% predicted
4. Body mass index (BMI) < 18 kg/m2 or > 32 kg/m2
5. Pulmonary hypertension:
a) Peak systolic PAP > 45 mm Hg or Mean PAP > 35 mm Hg
b) Right heart catheter measurements will be considered
definitive over echocardiogram measurements
6. Inability to walk > 140 meters in 6 minutes (6MWD) following
optimized medical management and prescribed rehabilitation
7. Homogeneous disease and/or with highly diseased lower lobes
(Density - tissue to air ratio of <11%)
8. Clinical significant bronchiectasis
9. Pneumothorax or pleural effusions within previous 6 months
10. Heart and/or lung conditions, stroke, heart failure, transplant, lung
volume reduction or resection, bullectomy, or implantable cardiac
defibrillator implant
11. Recent COPD exacerbation in preceding 6 weeks, or > 3 COPD
related hospitalizations requiring antibiotics in past 12 months
12. Daily use of systemic steroids, > 5 mg prednisolone
13. Single large bulla (defined as > 1/3 volume of the lobe) in
upper lobe
14. Coagulopathy or current use of anticoagulants
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the current guidelines outlined by Good Clinical Practice
guidelines, the Declaration of Helsinki, and the Inter-
national Conference on Harmonisation.
All patients will undergo two screening phases. The initial
screening is completed within 30 days of randomization and
assesses patient eligibility as defined by the inclusion and ex-
clusion criteria. Because the NETT and STEP-UP trial both
have similar goals (i.e. achieve LVR), the NETT has been
used to establish many of the vapour ablation treatment cri-
teria. Additional criteria have also been established using re-
sults from the VAPOR trial. The STEP-UP trial inclusion
and exclusion criteria are outlined in Tables 2 and 3. De-
tailed STEP-UP trial inclusion/ exclusion criteria can be
found at http://clinicaltrials.gov/show/NCT01719263.
During the initial screening visit, patient demograph-
ics, smoking history, physical examination, pulmonary
and concomitant medication use, and medical history is
recorded. Additional screening also includes completing
SGRQ, Modified Medical Research Council Dyspnea Score,
COPD Assessment Test, post-bronchodilation body pleth-
ysmography, post-bronchodilation diffusing capacity of the
lungs for carbon monoxide (DLCO) test, 12-lead electro-
cardiography, arterial blood gas, six minute walk test, and a
high resolution computed tomography (HRCT) scan. The
HRCT scan will be used for procedure planning, assessing
inclusion criteria including heterogeneity of the disease andTable 2 The STEP-UP trial inclusion criteria
1. Age ≥ 40 and ≤ 75 years old
2. Heterogeneous emphysema with upper lobe predominance
in both lungs
3. FEV1 between 20% and 45% predicted
4. Total lung capacity (TLC) ≥ 100% predicted
5. Residual volume (RV) > 150% predicted
6. Post-rehabilitation 6-minute walk test > 140 meters
7. Marked dyspnea scoring > 2 on the modified Medical Research
Council scale (mMRC)
8. Arterial blood gas levels of: PaCO2 ≤ 50 mm Hg; PaO2 > 50 mm Hg
on room air
9. Non-smoking for 6 months prior to study enrollment
10. Optimized medical management (treatment consistent with
GOLD guidelines)
11. Evidence of completed pulmonary rehabilitation:
a) ≥ 6 weeks out-patient or ≥ 3 weeks in-patient within 6 months
of enrollment; or,
b) Patient has or continues to participate in regular physical
activity beyond activities of daily living (i.e. a walking program)
for ≥ 6 weeks under the supervision of a health care professional
12. Mentally and physically able to cooperate with the study
procedures and to provide informed consent to participate
in the study.lower lobe TAR, and generating treatment plans for both
treatment sessions.
The second screening visit is completed within 7 days
of randomization to define baseline data closer to the
randomization date and to ensure the patient still
qualifies. This visit will consist of a physical examin-
ation including vital signs, post-bronchodilation spirom-
etry, a review of the subject’s daily diary, concomitant
medications, adverse events, and exercise counselling.
A complete list of screening assessments is available at
http://clinicaltrials.gov/show/NCT01719263.Assessing heterogeneity for inclusion criteria
A patient HRCT will be acquired within 90 days of
randomization and will be used to assess patient eligibil-
ity, such as heterogeneity, and create patient treatment
plans for the first and second treatments. The process
for determining heterogeneity in the STEP-UP trial is
more quantifiable than the process used during the NETT,
where radiologists were assigned the task of qualitatively
determining heterogeneity. During the NETT trial, each
lung was divided into 3 zones and each zone was ranked
on a scale of 0–4 to represent the severity of emphysema
where 0 indicated no emphysema and 4 indicated a high
Figure 3 Hypothesized improvements in safety and efficacy
using the STEP-UP algorithm. The STEP-UP trial’s treatment
volume parameters lead to a hypothesized improvement in safety
and efficacy.
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of at least 2 in two of the three zones were considered het-
erogeneous [20]. This method, however, is subjective and
does not necessarily follow natural anatomical boundaries,
such as fissures. In the STEP-UP trial, quantitative CT
analysis is used to assess heterogeneity precisely along
anatomical boundaries. Tissue and air values are calcu-
lated for each segment using quantitative CT analysis. The
left upper lobe is comprised of 5 segments: LB1, LB2, LB3,
LB4, and LB5. LB4 and LB5 together form the lingula,
which is not considered for upper lobe predominant treat-
ment using vapour ablation. The right upper lobe is com-
prised of 3 segments: RB1, RB2, and RB3, all of which are
considered for upper lobe predominant treatment using
vapour ablation. The tissue and air values are used to
evaluate the tissue to air ratio (TAR), a measure of lung
density and disease state, for each segment and lobe. TAR
is then used to calculate the heterogeneity index (HI), a
ratio that evaluates the disease of the upper lobe relative
to the lower lobe. Because the STEP-UP trial targets treat-
ment of individual segments rather than an entire lobe,
the HI is calculated at a segmental level using segmental
TAR (Eq. 1). The STEP-UP heterogeneity inclusion criter-
ion requires all segments treated to have a baseline HI of
no less than 1.2.
Segmental HI :
Ipsilateral Lower Lobe TAR
Segmental TAR
ð1Þ
Assessing lower lobe TAR for inclusion criteria
Quantitative CT analysis is also used to evaluate lower
lobe TAR. A STEP-UP exclusion criterion is a lower lobe
TAR of less than 11%. Analyses of a small number of
previous vapour ablation cases (not shown) suggest pa-
tients with a baseline lower lobe TAR < 11% may have a
reduced safety profile in comparison to patients with a
baseline lower lobe TAR ≥ 11%.
Treatment algorithm
To pursue a balance of safety and efficacy, the following
treatment volume parameters have been set (Figure 3):
 Treat one preferentially most diseased segment
meeting segmental HI criteria during session 1.
 Treat up to two preferentially most diseased
segments meeting segmental HI criteria during
session 2.
 Treatment session 1 will target treatment of 50%
(±20%) of the upper lobe (referred to as the primary
lobe).
 Treatment session 2 will target 60% (±20%) of the
contralateral upper lobe (referred to as the
secondary lobe). Combination of both sessions will target treatment
of 110%* (+20%/-15%) of the two lobes treated.
 Volume treated per session to not exceed 1700 ml.
*Due to the anatomical tendency of the two upper
lobes to differ in size, the percentages treated per patient
cannot be combined to be evaluated out of 100%. In-
stead, one entire lobe is evaluated as 100% and the
combination of both lobes is evaluated as 200%.
The STEP-UP trial targets the most diseased segments as
defined by TAR (density). Because hyperinflation of the
lung causes air pockets to develop during emphysema,
density of the segment decreases as it becomes more
diseased [21]. Similarly, because TAR is a measure of lung
density, lower TAR is associated with the more diseased
segment. To consistently apply all criteria for segment se-
lection to each patient, a matrix of all possible treatment
options using the 3 available segments in each upper lobe
(left: LB1, LB2, LB3; right: RB1, RB2, RB3) is generated and
used for each patient. Note that LB1 and LB2 can be
combined to form LB1 + 2 and be treated as one segment.
How these segments are selected to optimally meet
these parameters is as follows. All possible treatment op-
tions are generated and considered where each treat-
ment option is treatment of 1 segment from the primary
lobe and up to two segments of the secondary lobe. Each
treatment option is evaluated to determine whether each
session and overall procedure meets the treatment
volume parameters and whether each segment meets HI
criteria (≥1.2). Any treatment options that do not meet
these criteria are removed. Next, the distribution of
emphysema disease within each upper lobe is evaluated.
Each segment is evaluated to determine which one is
the least diseased within a lobe. Segmental TAR is calcu-
lated for each segment to determine severity of disease
using quantitative CT analysis. Segments within a lobe
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considered equally diseased. Otherwise, the segment
with the smallest segmental TAR is considered to be
most diseased and the segment with the largest segmen-
tal TAR is considered to be least diseased. Any treat-
ment option proposing treatment of the least diseased
segment in an upper lobe is removed from consideration
unless all remaining treatment options treat such a seg-
ment. If only one treatment options remains, it will be
used as the preferred treatment plan. Otherwise, the
combined TAR of the upper lobe segments will be used
to determine the preferred treatment option (Eq. 2).
Combined TAR :
Seg: 1massþ Seg: 2massþ Seg: 3mass
Seg: 1 air vol: þ Seg:2 air vol: þ Seg: 3 air vol:
ð2Þ
Combined TAR compiles the segmental TAR associ-
ated with each segment in a treatment option to deter-
mine which one targets the most disease. The treatment
option with the lowest combined TAR treats the most
disease and is therefore chosen to pursue a treatment
plan. However, any treatment options within 0.30% com-
bined TAR are considered to be treating similar amounts
of disease. If two or more treatment options are consid-
ered to be treating a similar amount of disease, the treat-
ment option that is closer to treating the target volume
of 110% of the patient’s upper lobes will be used to pur-
sue the patient’s preferred personalized treatment plan.
Primary and secondary endpoints
The STEP-UP primary endpoints are the change in FEV1
(% predicted) and SGRQ score between the treatment and
control arm at 12 months. Adverse events will be moni-
tored over the course of the study and be considered as
secondary endpoints along with other efficacy outcomes
at 6 and 12 months such as lung volumes, mMRC, SGRQ,
DLCO, 6MWT. LVR from a 6 month follow-up HRCT
will also be a secondary efficacy endpoint for the treat-
ment group.
Patient schedule and follow up
Patients will be randomized at a 2:1 ratio to the treat-
ment arm. These patients will receive standard medical
management and vapour ablation treatment over the
course of two sessions. The first treatment session will
take place within 7 days of randomization and will be
denoted as study day 1. The second treatment session
will be scheduled 13 weeks after the first treatment ses-
sion (+/− 7 days). However, the treating physician may
delay the second treatment session by up to 4 weeks if the
chest x-ray or inflammatory markers indicate the healing
process has not completed prior to the second treatment
session. After each treatment session, patients should con-
tinue prophylactic broad spectrum antibiotics ≥ 14 days,remain active, and be encouraged to incorporate regular
physical activity. If moderate to severe symptoms occur,
patients should be informed to contact their treating
physician. Moderate to severe symptoms are treated
with increased bronchodilators, antibiotics and oral
steroids. One third of the patients will be randomized
to the control arm and will receive standard medical
management alone without vapour ablation treatment.
The date of randomization is denoted as study day 1
for control arm patients.
Patient follow-up visits will be scheduled as telephone
calls and in-person clinic visits. During telephone calls,
research coordinators or trained designees will review
the daily diary, record any change in medications, any
occurrence of adverse events, and review exercise coun-
selling. The clinic visits will consist of a physical exam,
review of vital signs, review of medication, and review of
any adverse events that may have occurred since the
previous follow-up visit or telephone call. If a COPD ex-
acerbation occurs during the conduct of the clinical trial,
treatment of the exacerbation should follow standard
medical care and may include the addition of, or in-
crease in systemic corticosteroids (generally prescribed
for up to 2 weeks) and/or antibiotics. In the case of severe
exacerbations, any and all therapies and interventions
deemed medically necessary by the treating physician may
be prescribed.
Telephone calls will be scheduled at 1, 4, 14, 17, 32,
and 45 weeks and in-person clinic visits will be sched-
uled at 2, 8, 12, 15, 21, 26, 39 and 52 weeks (Figure 4).
Control patients will not be scheduled for the follow-up
visits at weeks 1, 14 and 15. Also, week 2 will be sched-
uled as telephone calls rather than clinic visits for pa-
tients randomized to the control arm. A HRCT will also
be acquired at the 6 month timeline for the treatment arm
only, which will be used to assess LVR post-treatment.
Analysis
A two-sample t test was used to determine the sample
size for the study based on the two primary endpoints.
An assumption of a 12% predicted difference in FEV1
between the treatment arm and the control arm at
12 months with an assumed standard deviation of 15
leads to an intended sample size of 59 patients. An as-
sumption of an 11 point difference in SGRQ between
the treatment arm and the control arm at 12 months
with a standard deviation of 14 leads to an intended
sample size of 60 patients. However, to account for an
estimated 15% loss during patient follow-up, the sample
size was increased by 15% resulting in an intended sam-
ple size of 69 patients. The sample size was calculated
using an 80% power, a Type I error rate of 0.05 and a 2:1
randomization allocation. The calculation was computed
using Power Analysis and Sample Size 11 software.
Figure 4 Patient follow-up visit schedule. *The HRCT scanned for the screening process can be acquired up to 90 days before randomization.
FU = follow-up.
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for the multiple comparisons resulting from two end-
points and evaluate if the primary endpoint has been
reached. The Hochberg method allows for two different
scenarios to determine achievement of the primary end-
point for a positive trial:
1. If both primary endpoints (FEV1 %predicted and
SGRQ) reach clinical significance at the 0.05 level.
OR
2. If either one of the two endpoints (FEV1 %predicted
or SGRQ) reach clinical significance at the 0.025
level.
Additionally, a binary responder rate analysis will be
performed, where a responder is identified for the fol-
lowing secondary endpoints as:
 %predicted FEV1 ≥ 12% difference from baseline
 SGRQ ≥ 8 points difference from baseline
 6MWT ≥ 30 meters from baseline
Primary endpoint analysis will be based on the 12 month
visit. If data is not available due to a serious adverse event,
including death, then the worst prior follow-up value will
be used. If data is missing in other cases, the last available
value from prior visits will be used. If no follow-up data is
available, an intent-to-treat analysis will use the baseline
values. A sensitivity analysis will be presented excluding
such patients.
Safety
A Data Safety Monitoring Board (DSMB) and Clinical
Events Committee (CEC) are in place to closely and
independently monitor the safety of the STEP-UP trial.
Reports outlining these occurrences will be generated on
a frequent periodic basis unless the DSMB/CEC requests
the reports more often. DSMB/CEC will conduct a
review at a minimum for the first and second treatment
of the first 15, 30 and 46 patients.
Discussion
The NETT established that although LVRS may lead to
clinically relevant improvement for patients with ULPE,
the treatment is also associated with a high risk profile.
To minimize these risks, LVR can be induced bronchos-
copically via vapour ablation. Pilot studies for vapour
ablation, including the VAPOR trial, have demonstrated
successful LVR and clinically significant improvement for
patients treated unilaterally with vapour ablation [5,10].
The STEP-UP trial has been established to investigate a
bilateral sequential segmental approach for vapour abla-
tion and has been designed to conserve a balance between
the treatment’s safety and efficacy profiles.Vapour ablation treatment ablates emphysematous tis-
sue resulting in a reduction of lung volume and hyperin-
flation. Each STEP-UP procedure will consist of two
treatment sessions and each session will treat smaller
volumes of lung in comparison to VAPOR. This is
expected to reduce the occurrence of SAEs during the
STEP-UP trial due to correlation defined previously
between amount of lung treated per session and rate of
SAEs. In addition to reducing the amount of energy
delivered per session, treating over the course of two
sessions typically allows a larger volume of lung to be
treated during the entire procedure in comparison to the
VAPOR trial. The increase in total volume treated per
procedure is anticipated to improve efficacy while less-
ening the amount of energy delivered in one session is
anticipated to improve safety.
The severity of disease of each segment targeted for
treatment is also anticipated to affect the improvement
in efficacy. Due to vapour ablation’s ability to treat in the
presence of CV, the treatment can specify and target
individual segments. The STEP-UP trial explores the
approach of targeting only the most diseased segments
for treatment of both upper lobes to allow the less
diseased segments to continue lung functionality.
Furthermore, studies have demonstrated that the lar-
ger the heterogeneity, the more efficacious the outcomes
are post-LVRS [22,23]. This has also held true for LVR
induced via treatment using an alternate bronchoscopic
method (endobronchial valves), where larger heterogen-
eity showed correlation with improvements in FEV1 and
6MWT [24]. This indicates that LVR is most beneficial
when reducing the most diseased portions of the lung.
Because LVR has traditionally been induced at the lobar
level, heterogeneity has also traditionally been defined as
the difference in disease state between ipsilateral lobes.
However, because the STEP-UP trial targets individual
segments for treatment, it is important to apply the idea
of heterogeneity at the segmental level. Segments within
a lobe are not necessarily equivalently diseased and ap-
plying heterogeneity at the segmental level determines a
segment’s disease state in comparison to the remaining
lobe as well as disease state in comparison to the ipsilat-
eral lower lobe. This helps in identifying the segment that
is least contributing to healthy pulmonary function or
conversely most contributing to poor pulmonary function.
The segments that are relatively less diseased in compari-
son to the remaining emphysematous upper lobe and lung
positively contribute to pulmonary function and should
therefore be conserved.
If we look to the future potential of bronchoscopic
LVR in general and vapour therapy in particular we note
that 1) due to the progressive nature of emphysema, the
segments are expected to worsen overtime causing pul-
monary function to decline, 2) because not all segments
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proach may potentially also be utilized in the future as a
follow-up treatment for patients who have previously
been treated for emphysema and 3) a focused segmental
approach across all affected lobes might elucidate thera-
peutic targets in whole patient populations previously
generalized as having a diffuse disease.
Study limitations
One limitation of the study is the difficulty to fully blind
the trial. A fully blinded approach accentuates the scien-
tific merit of the study results and was therefore consid-
ered, but was deemed not appropriate for this study. A
single or double blinded approach would require control
patients to undergo two false bronchoscopy sessions over
the course of the study while under local anesthesia. This
would present unnecessary and ethically questionable risk
to the patients and was therefore decided to not be appro-
priate for this study. For this reason, the investigator and
patient are aware of the treatment status. However, the
investigators, patients, and sponsors, are blinded from
the summary statistics during the treatment phase of
the study.
Conclusion
The effects of emphysema are dependent on the hetero-
geneity and severity of the disease. Significantly affected
regions are depicted by low density areas on HRCT and
have greater parenchymal destruction resulting in hyper-
inflation and reduced pulmonary function. For this rea-
son, it is hypothesized that the ability to specifically
reduce the most emphysematous segments will yield the
most effective results. Previously, the NETT trial visually
assessed heterogeneity to determine upper and lower
lobe predominance. Results demonstrated that the more
diseased the reduced lung region and the less diseased
the remaining lung region, the greater the clinical im-
provement for the patient. Similarly, the VAPOR trial
also assessed heterogeneity of the lung to typically re-
duce an entire lobe during one session using vapour ab-
lation resulting in clinical benefit. The STEP-UP trial is
able to take this proven concept of effective volume re-
duction from the lobar level of the NETT and VAPOR
studies and apply it to the segmental level by virtue of
the fact that vapour ablation uniquely achieves volume
reduction in the presence of CV. A potential advantage
of the STEP-UP trial is an improved safety profile over
the NETT and VAPOR studies. The STEP-UP trial’s al-
gorithm treats relatively small amounts of volume over-
time leading to delivery of relatively small amounts of
energy to a patient during each session. Additionally,
there is potential for improved efficacy by treating only the
most diseased segments and thereby leaving less diseased
segments intact to contribute to pulmonary function post-procedure. These segments will be treated over the course
of two sessions to allow larger diseased portions of the lung
to be treated per patient without increasing the energy de-
livered per session. The STEP-UP trial results will elucidate
whether the hypothesis and associated benefits presented
in this paper hold true.
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